ANTI-DEspR INHIBITORS AS THERAPEUTICS FOR INHIBITION OF PATHOLOGICAL ANGIOGENESIS AND TUMOR CELL INVASIVENESS AND FOR MOLECULAR IMAGING AND TARGETED DELIVERY
AssigneeTrustees of Boston University
InventorsNelson Ruiz-Opazo, Victoria L.M. Herrera
Life of this patent
Estimating the term…
Abstract
Provided herein are novel compositions comprising anti-DEspR antibodies and fragments thereof, including fully human, composite engineered human, humanized, monoclonal, and polyclonal anto-DEspR antibodies and fragments thereof, and methods of their use in a variety of therapeutic applications. The compositions comprising the anti-DEspR antibodies and fragments thereof described herein are useful in diagnostic and imaging methods, such as DEspR-targeted molecular imaging of angiogenesis, and for companion diagnostic and/or in vivo-non invasive imaging and/or assessments.
Claims93
A method of treatment comprising administering to a human subject within two days of the subject having a stroke a DEspR inhibitor in an amount effective to treat the stroke.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled) .
(canceled)
A method of inhibiting an adverse neurological event comprising, administering to a human subject having or suspected of having micro-hemorrhages a DEspR inhibitor in an amount effective to inhibit the adverse neurological event.
(canceled)
(canceled)
(canceled)
A method of treating cancer comprising administering to a subject having a cancer expressing DEspR an antibody or fragment thereof that binds selectively to VEGFsp in an amount effective to inhibit the cancer.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A method of inhibiting angiogenesis comprising administering to a subject having a disease or disorder dependent on or modulated by angiogenesis, an antibody or fragment thereof that binds selectively VEGFsp in an amount effective to inhibit the angiogenesis.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A pharmaceutical preparation comprising a human or humanized antibody or fragment thereof that binds selectively VEGFsp and a pharmaceutically acceptable carrier constructed and arranged for administration to a human.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A composition comprising VEGFsp, or a fragment thereof that binds DEspR, coupled to a toxin.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A method for identifying a circulating tumor cell comprising contacting a circulating tumor cell expressing DEspR with an agent that binds DEspR, and detecting the agent bound to the circulating tumor cell.
(canceled)
(canceled)
Dependencies are inferred from the claim text.